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A multinational, multicentre, randomized, prospective, parallel-group study compared treatment with ciprofloxacin 
administered as an oral suspension (500 mg twice daily for 7 days) with co-amoxiclav tablets (625 mg three times 
daily for 7 days) in patients suffering from acute exacerbations of chronic bronchitis (AECB). 
A total of 147 of 165 cases treated with ciprofloxacin (89.1%) and 146 of 162 cases treated with co-amoxiclav 
(90.1%) were classified as being clinical successes at the primary efficacy assessment 7 days after the end of therapy 
(assessed as reduced cough, improvement in dyspnoea, reduction in 24-h sputum volume or reduced purulence 
of sputum). Treatment equivalence was statistically confirmed; treatment difference: - l.O%, 95% CI - 6.6% 
and 4.5%. 
Before treatment, 128 bacterial strains were isolated from 103 patients (60 ciprofloxacin and 68 co-amoxiclav). 
The most commonly isolated organism was Haemophilus influenzae (60 isolates), followed by Moraxella catarrhalis 
(12 isolates), Streptococcus pneumoniae (11 isolates) and Staphylococcus aureus (10 isolates). At day 14, 40 of 46 
ciprofloxacin-treated patients (87.0%) and 46 of 55 co-amoxiclav-treated patients (83.6%) who were valid for 
bacteriological analysis were classified as being bacteriological successes (classed as eradication, eradication with 
colonization or presumed eradication; treatment difference: 3.3%, 95% CI - 8.3% and 14.9%). 
The adverse event profile was comparable between treatment groups. Most adverse events considered possibly or 
probably related to study drug were related to the gastrointestinal system and were of mild or moderate severity: 
nausea (13% ciprofloxacin, 10.6% co-amoxiclav), flatulence (10.3% ciprofloxacin, 3.9% co-amoxiclav), abdominal 
pain (7.6% ciprofloxacin, 7.3% co-amoxiclav) and diarrhoea (4.3% ciprofloxacin, 6.7% co-amoxiclav). 
We concluded that a 7-day course of ciprofloxacin suspension is equivalent to a 7-day course of co-amoxiclav 
tablets in terms of clinical and bacteriological efficacy and tolerability for the treatment of AECB. Thus, 
ciprofloxacin suspension may offer a suitable alternative treatment for AECB patients who have difficulty in 
swallowing, or who prefer liquid medications to tablets. 
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Introduction 
Acute exacerbations of chronic bronchitis (AECB) are 
generally characterized by increased cough, dyspnoea, and 
sputum production (1,2). The pathogen most often associ- 
ated with AECB is Haemophilus injfuenzae, accounting for 
more than 50% of all bacterial exacerbations (2-4). Other 
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organisms associated with AECB include Moraxella 
catarrhalis, Streptococcus pneumoniae and Haemophilus 
parainjluenzae, with a smaller incidence of Klebsiella spp. 
and Pseudomonas spp. (l-3). 
Most patients with AECB in primary care are treated 
with antibiotics, but there is increasing anxiety about 
the effectiveness of many of the currently used first-line 
antibiotics. Resistance to penicillins and cephalosporins 
continues to increase world-wide, especially amongst 
b-lactamase-producing bacteria such as H. injluenzae and 
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AL catarrhalis, and the prevalence of S. pneumoniae strains 
resistant to penicillins and other antibiotics is also rising 
(5-7). 
Ciprofloxacin is a 4-fluoroquinolone with a broad anti- 
bacterial spectrum against both Gram-negative and Gram- 
positive organisms. It does not have ideal activity against 
S. pneumoniae, but clinical studies on AECB have shown 
that ciprofloxacin is at least as effective as comparator 
antibiotics (8-16). The drug is 85% bioavailable after oral 
administration and has excellent tissue distribution (17,18). 
Ciprofloxacin, like other fluoroquinolones, acts by inter- 
action with DNA gyrase, a bacterial topoisomerase that is 
responsible for negative super-coiling of DNA within the 
bacterial cell ( 19). 
The new ciprofloxacin oral suspension has comparable 
pharmacokinetics to the tablet formulation of the drug 
(data on file, Bayer AG, Wuppertal, Germany) and 
food has no significant effect on the absorption of this 
new formulation (data on file, Bayer AG, Wuppertal, 
Germany). Ease of administration of an oral medication is 
particularly important for patients for whom swallowing is 
difficult, such as the elderly, and patients with anatomical 
or dysfunctional problems. 
The aim of this study was to compare the efficacy and 
tolerability of a ciprofloxacin oral suspension (500 mg twice 
daily for 7 days) with that of co-amoxiclav (625 mg three 
times daily for 7 days), an antibiotic of known therapeutic 
value in lower respiratory tract infections, in a large 
population who suffered AECB with a high likelihood of 
bacterial aetiology. 
Methods 
This was a randomized, prospective, open, parallel group, 
multinational comparative study carried out at 50 centres in 
four countries: France, Germany, Spain and the U.K. 
Independent ethics committees approved the study and 
patients gave written informed consent before participation 
in the study. 
PATIENTS 
Patients were randomized to treatment between 28 April 
1995 and 7 May 1997. Patients were screened by their 
physician for eligibility to enter the study. In order to be 
eligible, they had to be diagnosed with chronic bronchitis, 
defined as a chronic cough productive of sputum for 3 
consecutive months in 2 consecutive years, with an acute 
exacerbation indicated by the production of purulentl 
mucopurulent sputum and at least one of the following 
signs: increasing dyspnoea and/or increasing sputum vol- 
ume. Chest X-rays were performed on all randomized 
patients pre-treatment. 
Patients were excluded from study participation because 
of known allergy to the study antibiotics, pregnancy and 
lactation, significant renal or hepatic impairment, concomi- 
tant serious illness, recent antibiotic therapy and recent 
participation in another clinical trial. 
ANTIBIOTIC THERAPY 
Patients were randomized to receive either ciprofloxacin 
suspension as a 10% solution (equivalent to 500 mg) bid for 
7 days or oral co-amoxiclav 625 tablets (500 mg amoxicillin, 
125 mg clavulanate) tid for 7 days. Medications were 
allowed to be taken either before or after meals. The study 
drugs were administered in an open, non-blind fashion. 
CLINICAL AND BACTERIOLOGICAL 
EVALUATIONS 
Patients were assessed pre-therapy (day 0), at the end of 
treatment (day 7) and 7 days after treatment had ended 
(day 14). They were contacted at monthly intervals there- 
after for 6 months. The investigators could withdraw 
patients from the study at any time if adverse events 
occurred or if the study drug was judged to be ineffective. 
Clinical assessments were based on reduced cough, 
improvement in dyspnoea, reduction in 24-h sputum vol- 
ume or reduced purulence of sputum, all of which were 
graded according to predefined scales. 
Sputum samples for culture were collected before treat- 
ment, on days 7 and 14, when available at the end of 
therapy, and if treatment failure occurred. The number of 
samples obtained at each time point was as follows: 327 at 
visit l/day 0 (165 ciprofloxacin and 162 co-amoxiclav), 293 
at visit 2/day 7 (147 ciprofloxacin and 146 co-amoxiclav), 
and 241 at visit 3/day 14 (113 ciprofloxacin and 128 
co-amoxiclav). At first exacerbation, a total of 82 sputum 
samples was collected (44 ciprofloxacin and 38 
co-amoxiclav). The quality of sputum was assessed accord- 
ing to published recommendations (20). Recent data 
suggest that only sputum samples with 225 polymorpho- 
nuclear granulocytes (PMNs) per x 100 microscopic field 
should be included to increase the likelihood that cultured 
organisms were indeed ‘causative’ of AECB (21). However, 
review of the samples showed that there was no difference 
in the growth patterns of organisms between samples with 
PMN 225 per x 100 field and samples with ~25 PMN per 
x 100 field. Therefore, all samples were analysed as one 
population. 
Assessments were also made of clinical signs and symp- 
toms (wheeze, malaise, dyspnoea, cough and exercise 
intolerance). 
The clinical response at day 14, 7 days after termination 
of antibiotic therapy, was the primary efficacy variable and 
was assessed as: (i) cure (resolution of signs and symptoms), 
(ii) improvement (subjective improvement of symptoms), 
(iii) failure (no resolution of signs and symptoms), (iv) 
relapse (at day 14 only, an initial resolution of signs and 
symptoms during study drug administration but subsequent 
worsening of signs and symptoms) or (v) indeterminate 
(not evaluable). Clinical success was defined as cure or 
improvement at days 7 and 14. Patients who did not 
have clinical improvement, or whose condition worsened 
by day 7, were deemed treatment failures. Secondary 
assessments were clinical response at day 7, and time to 
subsequent exacerbation in patients considered clinically 
cured at day 14. 
254 R. c. REA!~ ET AL. 
TABLE 1. Reasons for withdrawal during treatment 
Reason for withdrawal 
Ciprofloxacin 
500 mg twice daily 
(n= 185) 
Patients (n (%) 
Co-amoxiclav 
625 mg three times daily 
(n= 179) 
Overall 
(n=364) 
Adverse event 2 (1) 1 (0.5) 3 (1) 
Consent withdrawn 1 (0.5) 0 1 (0.25) 
Lost to follow-up 0 2 (1) 2 (0.5) 
Non-compliance 1 (0.5) 0 1 (0.25) 
Total 4 (2) 3 (2) 7 (2) 
Minimum inhibitory concentrations (MICs) of anti- 
biotics for the isolated organisms were determined using 
E-test strips (AB Biodisk, Sweden). 
SAFETY EVALUATIONS 
Blood and urine samples were collected before treatment 
and at the end of treatment (day 7) for clinical chem- 
istry, haematology and urinalysis. Adverse events were 
coded using COSTART terms and were assessed for 
frequency, duration, severity, outcome and relationship to 
study drug. 
STATISTICAL ANALYSIS 
It was calculated that 332 valid patients would be needed 
for a power to show equivalence of 80% where the true 
difference between treatments was 0%, and for a signiti- 
cance level of 5% where the true difference between treat- 
ments was 10%. It was anticipated that 440 patients would 
need to have been recruited to obtain 332 valid patients. 
However, interim analysis showed that fewer patients were 
needed and recruitment was prematurely terminated after 
364 patients had been entered. From these 364 patients, 327 
valid patients were obtained, which was sufficient to main- 
tain the power of the study and allow the primary objective 
of the study to be met. 
The clinical response at days 14 (primary assessment) 
and 7 (secondary assessment) was analysed using 95% 
confidence intervals (CI) from the exact test for the com- 
mon odds ratio, after homogeneity of the odds ratio 
between treatment centres had been assessed using the 
Zelen test. The bacteriological response was analysed in the 
same way. 
The time to the next exacerbation was analysed using the 
Kaplan-Meier estimate of freedom from signs and symp- 
toms. Equivalence of exacerbation-free profiles between 
ciprofloxacin and co-amoxiclav treatments was assessed 
using the log-rank, Breslow and Tarone-Ware tests: The 
95% confidence intervals of the treatment differences were 
calculated for each analysis. 
Results 
A total of 364 patients was randomized to treatment, of 
whom 185 (510/) were randomized to receive ciprofloxacin 
and 179 (49%) to receive co-amoxiclav. All but one of the 
patients were included in the safety analyses; this patient 
did not receive study medication. A further 36 patients were 
excluded from the valid for efficacy population and thus, 
327 (90%) patients were considered evaluable for efficacy 
(165 ciprofloxacin and 162 co-amoxiclav). A total of seven 
patients withdrew during the 7-day treatment period, three 
of whom were withdrawn due to adverse events (Table 1). 
The demographic characteristics of the two treatment 
groups valid for efficacy were very similar (Table 2). Over 
66% of patients in both treatment groups were either 
current or previously active smokers. Many patients 
received concomitant medication, the most frequently used 
being (percentage of patients): salbutamol (29%) beclom- 
ethasone (22%), theophylline (15%), prednisolone (14%) 
and ipratropium (10%). A total of 103/327 (31%) patients 
had valid bacteriological data at day 7 and 1021327 (31%) 
were considered bacteriologically evaluable at day 14, i.e. 
their bacteriological evaluation was not either ‘missing’ or 
‘indeterminate’, and they had provided a bacteriologically 
positive pretreatment sputum sample. 
CLINICAL RESPONSE 
The clinical response of patients at day 7 (end of treatment) 
and day 14 is summarized in Fig. 1. At day 7, of the 327 
clinically evaluable patients, 96% of both ciprofloxacin- 
(159 of 165 subjects) and co-amoxiclav-treated (156 of 162 
subjects) patients were considered clinical successes (cured 
or improved). The clinical equivalence of the two treat- 
ments was confirmed by the 95% CI (treatment difference: 
O*l%, 95% CI - 3.4% and 3.5%). This clinical success rate 
was maintained to day 14, 7 days after termination of 
treatment: 89% (147 of 165 subjects) of ciprofloxacin and 
90% (146 of 162 subjects) of co-amoxiclav-treated patients 
were still considered clinical successes. The clinical equiva- 
lence of the two treatments was again confirmed by the 
95% CI (treatment difference: - l.O%, 95% CI - 6.6% 
and 4.5%). 1- L 
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TABLE 2. Baseline and demographic characteristics of patients (efficacy valid population) 
Characteristic 
Ciprofloxacin 500 mg Co-amoxiclav 625 mg 
once daily three times daily 
Patients (n) 
Sex [n (“/)I 
Male 
Female 
Mean f SD age [years (range)] 
Mean & SD weight [kg (range)] 
Mean f SD height [cm (range)] 
Smoking habits [n (%)I 
Never smoked 
Previous smoker 
Smoker 
Passive smoker 
Median no. of exacerbations in previous year 
(min, max) 
Coexistent cardiopulmonary disease [n (%)] 
165 
93 (56) 
72 (44) 
63 f 14.4 (19-95) 
72 h 16.3 (37-137) 
167 f 8.5 (1499185) 
40 (24) 
75 (46) 
49 (30) 
1 (1) 
3 (0; 15) 
39 (21.2) 
162 
96 (59) 
66 (41) 
60 f 14.6 (18-88) 
73 f 14.7 (42-105) 
168 f 10.0 (140-195) 
44 (27) 
65 (40) 
52 (32). 
1 (1) 
3 a 12) 
33 (18.4) ,. 
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FIG. 1. Percentages of patients receiving ciprofloxacin or co-amoxiclav classified as being ‘successes’ [clinical cure (H) or 
improvement (O)] at days 7 and 14. 
The clinical success rates at days 7 and 14 were similar for 
both treatments in the group of patients with valid bacterio- 
logical data. At day 14, 85% (40 out of 47 subjects) of 
ciprofloxacin and 89% (49 out of 55 subjects) of co-amoxiclav 
patients for whom valid bacteriological data was available 
were considered clinical successes and the clinical equiva- 
lence of the two treatments was confirmed by the 95% CI 
(treatment difference: - 4*0%, 95% CI - 15.0% and 7.0%). 
CLINICAL SIGNS AND SYMPTOMS 
Overall, the clinical signs and symptoms of acute in- 
fection (wheeze, malaise, cough, exercise intolerance, 
sputum colour, and sputum volume) showed continual 
improvement from baseline to day 14 of the study. 
There were no differences between the ciprofloxacin and 
co-amoxiclav treatment groups. 
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TABLE 3. Bacteriological response at days 7 and 14 in patients with valid bacteriological data 
, Ciprofloxacin 500 mg Co-amoxiclav 625 mg 
Day and response once daily three times daily 
Day 7 
succ4?ss [n (%)] 
Eradication 
Presumed eradication 
Eradication/colonization 
Failure [n (%)] 
Persistence 
Persistence/colonization 
Recurrence 
Eradicationlre-infection 
Indeterminate 
’ Day 14 
success [n (“!)I 
Eradication 
Presumed eradication 
Eradication/colonization 
Failure [n (%)] 
Persistence 
Persistence/colonization 
Recurrence 
Eradicationlre-infection 
Indeterminate 
40 (85) 46 (84) 
30 (63) 32 (58) 
4 (8) 6 (11) 
6 (13) 8 (15) 
7 (15) 9 (16) 
7 (15) 7 (12) 
0 1 (2) 
0 0 
0 1 (2) 
1 (2) 0 
40 (87) 46 (84) 
14 (30) 15 (28) 
2 (4) 4 (7) 
24 (51) 27 (49) 
6 (13) 9 (16) 
5 (11) 3 (5) 
0 l(2) 
0 2 (4) 
1 (2) 3 (5) 
1, (2) 0 
Before the start of treatment, 128 organisms were found in 103 patients. The bacteriological response 
shown in this table is based on these patients. 
BACTERIQLOGICAL RESPONSE BY PATIENT 
At day 7, the bacteriological success ‘rates (eradication, 
presumed eradication, or eradication with colonization) for 
bacteriologically evaluable patients was 85% (40 of 47 
subjects) for patients treated with ciprofloxacin and 84% 
(46 of 55 subjects) for patients treated with co-amoxiclav. 
Treatment equivalence was confirmed (treatment difference: 
1.5%, 95% CI - 10.4% and 13.3%). Similar bacteriological 
success rates at day 14 were also observed for patients 
treated with ciprofloxacin (40 of 46 patients; 87%) or 
co-amoxiclav (46 of 55 patients; 84%). Equivalence of the 
treatments was again confirmed by the 95% CI (treatment 
difference: 3.3%, 95% CI - 8.3% and 14.9%). Results are 
shown in Table 3. 
BACTERIOLOGICAL RESPONSE FOR 
INDIVIDUAL PATHOGENS 
At baseline, 128 organisms were isolated from 103 patients 
(31%): 60 from the ciprofloxacin group and 68 from the 
co-amoxiclav group. The frequency of isolation of indi- 
vidual micro-organisms at baseline, day 7, day 14 and 
fist exacerbation is shown in Table 4. Ciprofloxacin 
had a higher bacteriological success rate than co-amoxiclav 
for H. injuenzae, the most frequently isolated organism 
(601128, 47%). 
The number of S. pneumoniue isolates was low (combined 
1 l/128, 9%; ciprofloxacin 7/60, 11.7%; co-amoxiclav 4/68, 
5.9%); hence, it was difficult to compare the anti- 
pneumococcal bacteriological efficacy of the two treatment 
groups. The bacteriological efficacy for other organisms 
isolated was generally similar between the ciprofloxacin and 
co-amoxiclav treatment groups. There was a difference for 
the Enterobacteriaceae, where the isolation rates were simi- 
lar at baseline, but by day 7 all 22 isolates were from the 
co-amoxiclav treatment group, suggesting superinfection by 
members of this group. The presence of micro-organisms in 
sputum correlated poorly with treatment failure. A total of 
49 organisms were isolated at day 7 and 40 at day 14, but 
only five patients with organisms at day 7 and 11 with 
organisms at day 14 were considered clinical failures. 
All isolates of H. influenzae and H. parainjluenzae were 
susceptible to both study drugs (Table 5). Of the 11 
pneumococci isolated, all were susceptible to co-amoxiclav 
and eight were fully (MIC 2 1 mg 1 - ‘), and three moder- 
ately (MIC ~1 to <4), susceptible to ciprofloxacin. All of 
the organisms isolated at baseline were susceptible or 
moderately susceptible to ciprofloxacin except the Entero- 
bacteriuceue, where 5% of organisms were resistant. Of the 
organisms isolated from all patients, resistance rates against 
co-amoxiclav were 100% for P. aeruginosa, 33% for other 
Pseudomonas spp. and 16% for the Enterobacteriaceae (21% 
of the latter showed moderate susceptibility). The antibiotic 
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TABLE 5. Percentage of most frequently isolated strains susceptible to ciprofloxacin and co-amoxiclav 
Organism 
Percentage of susceptible isolates (total no. of isolates) 
Ciprofloxacin Co-amoxiclav 
Pre-treatment Day 7 Day 14 Pre-treatment Day 7 Day 14 
H. infuenzae 100 (60) 100 (7) 100 (7) 100 (60) 100 (7) 100 (7) 
H. parainfZuenzae 100 (4) 100 (2) 100 (4) NA 100 (2) 
M. catarrhalis 100 (12) 
lOZ1) 
100 (3) 92 (12) 100 (1) 100 (3) 
S. pneumoniae 73 (11) 33 (6) 100 (8) 100 (11) 100 (6) 100 (8) 
S. aureus 100 (10) 100 (1) 100 (6) 100 (10) 100 (1) 100 (6) 
P. aeruginosa 100 (6) 100 (4) 100 (6) 0 (6) 0 (4) 0 (6) 
Pseudomonas spp. 100 (3) 100 (6) 100 (2) 67 (3) 17 (6) 0 (2) 
Enterobacteriaceae 95 (19) 95 (22) 80 (5) 63 (19) 77 (22) 60 (5) 
NA = not available. 
susceptibilities of organisms isolated at day 7 and day 14 
were also determined. At day 7, four S. pneumoniae isolates 
were either resistant (n=2) or moderately susceptible 
(n=2) to ciprofloxacin and resistance to co-amoxiclav was 
observed for all four P. aeruginosa, five other Pseudo- 
monas spp., and five Enterobacteriaceae. At day 14, no 
isolates were resistant to ciprofloxacin (although moderate 
susceptibility to ciprofloxacin was documented in one 
Enterobacteriaceae isolate) whereas nine isolates were 
resistant to co-amoxiclav: five P. aeruginosa (in addition, 
one P. aeruginosa isolate was moderately susceptible), two 
Enterobacteriaceae and two other Pseudomonas spp. The 
short course of antibiotics used in this study did not cause 
any obvious development of antibiotic resistance. 
EXACERBATION-FREE INTERVAL 
The estimated percentage of patients who were considered 
clinical successes at day 14 and remained event-free for 6 
months after treatment without exacerbation was similar in 
both treatment groups: 63.7% f 4.5% of ciprofloxacin- 
treated patients (n=71) and 59% f 5.0% of co-amoxiclav- 
treated patients (n=66) (P=O*812; log-rank test). The mean 
exacerbation-free times for the whole study population by 
treatment group were: ciprofloxacin 163 days (95% CI 15 1, 
175 days) and co-amoxiclav 178 days (95% CI 165, 192 
days). This was supported by the analysis of patients with 
bacteriologically valid data at day 14 who were followed-up 
for 6 months: 47.7 f 8.5% of ciprofloxacin-treated patients 
(n= 16) and 51.9 f 7.4% of co-amoxiclav-treated patients 
(n=23) remained event-free for 6 months (P=O.788; log- 
rank test). There was no significant difference between the 
two treatment groups with respect to this analysis. 
ADVERSE EVENTS 
Two hundred and forty-four patients (67%) experienced an 
adverse event at some time during the study. Of these, 120 
(65%) received ciprofloxacin and 124 (69%) received 
co-amoxiclav. During and 7 days after treatment, 158 
patients (43.5%) experienced an adverse event: of these, 81 
(510/) received ciprofloxacin and 77 (49%) received 
co-amoxiclav. Most adverse events were mild or moderate 
in severity, with 12% of patients treated with ciprofloxacin 
and 11% of patients treated with co-amoxiclav having 
experienced adverse events considered severe. 
There were two deaths during the study (both in the 
ciprofloxacin group). None of these deaths was considered 
related to study treatment. Seven patients reported at least 
one serious adverse event, regardless of relationship to 
study drug, in the period during and 7 days post-treatment. 
Of these, one case of bronchitis (ciprofloxacin) was 
considered to be possibly or probably related to study 
medication. 
Withdrawals due to adverse events during and 7 days 
post-treatment occurred in 10 (5.4%) patients on cipro- 
floxacin and 10 (5.6%) on co-amoxiclav. Adverse events 
leading to treatment discontinuation and considered by the 
investigators to be either possibly or probably related to 
study medication were mostly diarrhoea (four co-amoxiclav 
patients) or nausea (two ciprofloxacin and three 
co-amoxiclav patients). 
The most frequent treatment-related adverse events 
(defined as being possibly or probably related to study drug 
therapy) during and 7 days post-treatment reported by 
ciprofloxacin- and co-amoxiclav-treated patients are shown 
in Table 6. The vast majority of adverse events were mild or 
moderate in intensity. 
CLINICAL LABORATORY TESTS AND 
VITAL SIGNS 
Most patients had normal haematological and clinical 
chemistry profiles at baseline, day 7 and day 14. Further- 
more, there was neither a significant increase nor decrease 
for any haematological or clinical chemistry parameter for 
either treatment group during this period. The greatest 
change in results was in total white blood cell counts, where 
19 patients in both treatment groups with high baseline 
values had values within the normal range at day 7. This 
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TABLE 6. Most frequent (occurring in at least 2% of study 
population) adverse events possibly or probably related to 
ciprofloxacin or co-amoxiclav treatment during and 7 days 
post-treatment 
Adverse events during 
and 7 days post-treatment 
Adverse event 
Ciprofloxacin Co-amoxiclav 
(n= 184) (n= 179) 
Nausea 24 (13.0%) 19 (10.6%) 
Flatulence 19 (10.3%) 7 (3.9%) 
Abdominal pain 14 (7.6%) 13 (7.3%) 
Diarrhoea 8 (4.3%) 12 (6.7%) 
Vomiting 9 (4.9%) 9 (50%) 
Dyspepsia 7 (3.8%) 3 (1.7%) 
shift was expected, and confirms the total white blood cell 
count as a good indicator of acute infection. 
No clinically relevant changes occurred in systolic and 
diastolic blood pressure or heart rate from baseline to 
day 14. 
Discussion 
Ciprofloxacin oral suspension has been developed to 
improve ease of antibiotic administration for those patients 
who find swallowing difficult, for example the elderly, and 
those with anatomical or dysfunctional swallowing prob- 
lems. Some patients who do not have such difficulties also 
prefer liquid medications to tablets. Previous studies have 
shown that this oral formulation has similar pharmaco- 
kinetics to the ciprofloxacin tablet (data on file, Bayer AG, 
Wuppertal, Germany), and that food has no significant 
effect on its absorption (data on file, Bayer AG, Wuppertal, 
Germany). This study was performed to assess the efficacy 
and safety of ciprofloxacin oral suspension compared with 
co-amoxiclav, a /?-lactam antibiotic considered as ‘gold 
standard’ in the treatment of AECB (22-31). 
The results of this study showed that a 7-day course of 
ciprofloxacin 500 mg oral suspension given twice daily was 
clinically equivalent to co-amoxiclav 625 mg tablets admin- 
istered three times daily. Both antibiotics produced high 
clinical success rates (96% for both drugs) at the end of 
treatment. This was maintained at 7 days post-treatment 
(day 14), with 89% of ciprofloxacin and 90% of 
co-amoxiclav patients still considered clinical successes. 
These findings are in agreement with previously reported 
clinical response rates between 80% and 95% for the 
treatment of AECB with ciprofloxacin (32-34). 
The organism most frequently isolated before treatment 
was H. infuenzae and the ciprofloxacin suspension was 
more effective than co-amoxiclav in eradicating this species. 
The numbers of H. infruenzae isolated in the ciprofloxacin 
group were 25 at pre-treatment, 1 at day 7 and 0 at day 14. 
The respective figures for co-amoxiclav were 35, 6 and 7. A 
comparatively high number of H. influenzae were isolated 
from patients in the co-amoxiclav treatment group, 
although all of these isolates were susceptible to 
co-amoxiclav at all visits when tested using the E-test for 
antibiotic susceptibility. However, results for the MIC and 
minimum bactericidal concentration (MBC) of an anti- 
biotic represent the net antibiotic effect over a fixed 
incubation period, and notable discrepancies between the 
bacteriological response - assessed by in vitro susceptibility 
testing-and the clinical response are common. Thus, 
in order to determine whether or not an organism is 
susceptible to an antibiotic, one needs to understand the 
pharmacokinetics of the drug (35). 
A number of pharmacokinetic surrogate relationships 
have been used to try to predict the outcome of antibiotic 
treatment (36), and the best predictor for /3-lactams, 
macrolides and /3-lactamlclavam combinations - such as 
co-amoxiclav- was the time that the plasma antibiotic 
concentration remained above the MIC for a particular 
organism (T>MIC) (37,38). In the case of co-amoxiclav, 
T>MIC,, for H. injluenzae was about 40% of the time for 
each dosage interval when the antibiotic was administered 
at a dose of either 875 mg bid or 500 mg tid (39). It has been 
shown that to approach maximum bacterial killing, cepha- 
losporin T>MIC needs to be for 60-70% of the dose period 
(40-43) whereas a bacteriostatic effect occurred when 
T>MIC was 40% of the dose period. Perhaps this could 
explain the persistence of H. ir$uenzae isolates in the 
co-amoxiclav treatment arm in this study. Conversely, 
ciprofloxacin - like other fluoroquinolones - exhibits 
concentration-dependent killing of bacteria (44,45), which 
could explain the lack of persistence of H. influenzae in the 
ciprofloxacin treatment group. 
Co-amoxiclav appeared to be more effective than cipro- 
floxacin in eradicating S. pneumoniae; however, the number 
of Streptococcus spp. isolated pre-treatment was small, 
making it difficult to compare the anti-pneumococcal 
bacteriological efficacy of the two treatment groups. The 
numbers of S. pneumoniae isolated in the ciprofloxacin 
group were seven at pre-treatment, five at day 7 and five at 
day 14. The corresponding figures for co-amoxiclav were 
four, one and three. In contrast, co-amoxiclav-treated 
patients appeared to be more susceptible to superinfection 
by Enterobacteriaceae following antibiotic treatment than 
were ciprofloxacin-treated patients. Pre-treatment isolation 
rates of the Enterobacteriaceae were seven (ciprofloxacin) 
and 12 (co-amoxiclav), but at day 7 all 22 cases of Entero- 
bacteriaceae isolated were in the co-amoxiclav group. At 
day 14, the isolation rates were three (ciprofloxacin) and 
two (co-amoxiclav). 
No differences between ciprofloxacin and co-amoxiclav 
treatments were observed for time to next exacerbation. 
Thus, it would appear unlikely that short antibiotic treat- 
ment regimens can influence the course of a chronic disease 
that is associated with significant epithelial cell damage. 
The frequency of adverse events in this study was as 
expected in this group of patients and comparable between 
the treatment groups. Most drug-related adverse events 
were gastrointestinal in nature, with no relevant qualitative 
differences between the two treatments. 
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In conclusion, ciprofloxacin suspension was clinically 
equivalent to the widely used first-line treatment of 
co-amoxiclav tablets, and there were no differences between 
the safety profiles of the two antibiotics. Based on the 
results of this study, together with other published data, 
we would suggest that ciprofloxacin oral suspension offers 
an alternative treatment of choice for AECB patients, 
especially those who have difficulties in swallowing, or who 
prefer liquid medications to tablets. 
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